Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease
Hepatology Research · 2024-07 · 54 (7) · 655-666
DOI: 10.1111/hepr.14020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 31.01.2024. Verfasst von Masahito Nakano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: EA Pharma Co., Ltd., Otsuka Pharmaceutical, This work was supported by MHLW Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus Program,.
Abstract (Originalsprache)
Aim
In patients with steatotic liver disease (SLD), significant hepatic fibrosis is a prognostic factor with various etiologies, including inflammation and metabolic dysfunction. This study aimed to investigate independent factors and profiles associated with significant hepatic fibrosis, including alanine aminotransferase (ALT) levels >30 U/L and metabolic dysfunction‐associated SLD (MASLD), in health check‐up examinees.
Methods
This single‐center, retrospective, observational cohort study enrolled 1378 consecutive health checkup examinees from April 2018 to September 2022. Shear wave elastography (SWE) was performed during a routine ultrasound examination, and patients with liver stiffness ≥6.60 kPa were defined as having significant hepatic fibrosis. Patients were classified into nonsignificant hepatic fibrosis ( n = 1220) or a significant hepatic fibrosis ( n = 158) group according to this definition.
Results
In multivariate analysis, the independent factor for significant hepatic fibrosis was aging (≥65 years; OR 9.637, 95% CI 6.704–13.852, p < 0.0001). According to decision tree analysis, the initial classifier was aging (≥65 years). After aging, an ALT level >30 U/L was the second relevant factor for significant hepatic fibrosis, regardless of age. An undirected graphical model showed that an ALT level of >30 U/L was directly associated with significant hepatic fibrosis. In patients aged ≥65 years with an ALT level >30 U/L, significant hepatic fibrosis was observed in 52% of the patients. Meanwhile, in patients aged ≥65 years with an ALT level ≤30 U/L, MASLD was the third classifier, with significant hepatic fibrosis observed in 38% of patients.
Conclusions
ALT levels >30 U/L and MASLD may be involved in the pathogenesis of significant hepatic fibrosis in patients aged ≥65 years.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Gastroenterology, Nara Medical University, Kashihara, Japan.
ORCID-Profile: Masahito Nakano, Takumi Kawaguchi
Förderung
- EA Pharma Co., Ltd.
- Otsuka Pharmaceutical
- This work was supported by MHLW Comprehensive Research on Life-Style Related Diseases including Cardiovascular Diseases and Diabetes Mellitus Program,
- Eisai
- ASKA Pharmaceutical
- AbbVie
- Janssen Japan
- Taisho Toyama Pharmaceutical Company
Zitieren
APA
Nakano, M., Kawaguchi, M., Kawaguchi, T., & Yoshiji, H. (2024). Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease. Hepatology Research, 54(7), 655-666. https://doi.org/10.1111/hepr.14020
Vancouver
Nakano M, Kawaguchi M, Kawaguchi T, Yoshiji H. Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease. Hepatology Research. 2024;54(7):655-666. doi:10.1111/hepr.14020
BibTeX
@article{Nakano2024,
author = {Nakano, Masahito and Kawaguchi, Machiko and Kawaguchi, Takumi and Yoshiji, Hitoshi},
title = {Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease},
journal = {Hepatology Research},
year = {2024},
volume = {54},
number = {7},
pages = {655--666},
doi = {10.1111/hepr.14020}
}
EUVIMED